Certuity LLC Invests $232,000 in Edwards Lifesciences Co. (NYSE:EW)

Certuity LLC acquired a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 3,128 shares of the medical research company’s stock, valued at approximately $232,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Bowman & Co S.C. boosted its position in shares of Edwards Lifesciences by 1.2% during the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock valued at $924,000 after buying an additional 148 shares during the last quarter. Mount Yale Investment Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 1.9% during the 4th quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock valued at $634,000 after acquiring an additional 162 shares during the last quarter. JFS Wealth Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 166 shares during the last quarter. Seascape Capital Management grew its stake in shares of Edwards Lifesciences by 0.5% in the third quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock worth $2,177,000 after acquiring an additional 174 shares during the period. Finally, Cooper Financial Group raised its holdings in shares of Edwards Lifesciences by 2.8% during the fourth quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock valued at $479,000 after purchasing an additional 175 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.75, for a total value of $492,375.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,555,402. This represents a 12.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 20,750 shares of company stock worth $1,564,255 in the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $75.96 on Friday. The stock has a 50-day moving average price of $72.51 and a 200 day moving average price of $69.36. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The stock has a market capitalization of $44.80 billion, a P/E ratio of 10.96, a P/E/G ratio of 3.64 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Equities research analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on EW. Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Citigroup upped their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Royal Bank of Canada reissued an “outperform” rating and issued a $85.00 target price on shares of Edwards Lifesciences in a research report on Wednesday. Truist Financial restated a “hold” rating and set a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Finally, Barclays increased their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.